, ).-N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At, Nuclear Medicine and Biology, vol.30, issue.4, pp.351-359, 2003.
, ).-Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation. Nuclear Medicine and Biology, 56 Supplement C, pp.10-20, 2018.
, ).-Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds, Bioconjugate Chemistry, vol.15, issue.1, pp.203-223, 2004.
, ).Targeted radionuclide therapy with astatine211: Oxidative dehalogenation of astatobenzoate conjugates, Scientific Reports, vol.7, issue.1, p.2579, 2017.
, ).Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein, Nuclear Medicine and Biology, vol.33, issue.4, pp.469-480, 2006.
, ).-Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins, Nuclear Medicine and Biology, vol.31, issue.8, pp.1061-1071, 2004.
, ).-Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds, Nuclear Medicine and Biology, vol.25, issue.4, pp.351-357, 1998.
, ).-Biodistribution of 211At labeled HER-2 binding affibody molecules in mice, Oncology reports, vol.17, issue.5, pp.1141-1147, 2007.
, ).-Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination, Bioconjugate Chemistry, vol.18, issue.4, pp.1226-1240, 2007.
, Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model, Blood, vol.125, issue.13, pp.2111-2119, 2015.
, STOLARZ (A.) et BILEWICZ (A.).-211At labeled substance P (5-11) as potential radiopharmaceutical for glioma treatment, Nuclear Medicine and Biology, vol.53, pp.1-8, 2017.
, BILEWICZ (A.) et ZALUTSKY (M.R.).-Stability and in vivo behavior of Rh, vol.42, pp.439-445, 2015.
, Radioiodinated and astatinated NHC rhodium complexes: synthesis. Nuclear Medicine and Biology, vol.41, pp.23-29, 2014.
, Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: Effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles, Journal of Nuclear Medicine, vol.46, issue.4, pp.700-706, 2005.
, ).-Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At ?-particles, Nuclear Medicine and Biology, vol.46, pp.43-49, 2017.
, ).-Intraperitoneal {alpha}-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab?)2-A phase I study, J. Nucl Med, vol.50, issue.7, pp.1153-1160, 2009.
, donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromeFull text view
, À lire également dans nos bases FRAYSSINET (P.).-Nanoparticules magnétiques en oncologie. Biomédical-Pharma, 2013.
, ).-Nanoparticules d'or multifonctionnelles pour l'imagerie et la thérapie. Biomédical-Pharma, 2014.
, VAUTHIER (C.) et COUVREUR (P.).-Nanotechnologies pour la thérapeutique et le diagnostic. Biomédical-Pharma, 2016.